Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123066 | 0.93 | HRH3 (0.44) | TLR9TLR7HRH3CNR2TP53 | |
| SCHEMBL4137164 | 0.91 | HRH3 (0.44) | TLR9TLR7HRH3CNR2TP53 | |
| SCHEMBL4127946 | 0.88 | CNR2 (0.58) | HRH3CNR2TP53MAPTNPC1 | |
| SCHEMBL4931840 | 0.85 | HRH3 (0.47) | TLR9TLR7HRH3TP53MAPT | |
| SCHEMBL4927925 | 0.85 | CNR2 (0.43) | HRH3CNR2TP53MAPTSCD | |
| SCHEMBL4130815 | 0.85 | HRH3 (0.52) | TLR9TLR7HRH3TP53MAPT | |
| SCHEMBL4130813 | 0.84 | HRH3 (0.46) | TLR9TLR7HRH3TP53MAPT | |
| SCHEMBL4134888 | 0.84 | FFAR4 (0.41) | HRH3CNR2TP53MAPTSCD | |
| SCHEMBL4935931 | 0.84 | TP53 (0.43) | HRH3CNR2TP53MAPTSCD | |
| SCHEMBL4140016 | 0.84 | CNR2 (0.44) | HRH3CNR2TP53MAPTSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | TLR9 1120/4885TLR7 1069/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.